Complement activation via the alternative pathway in a patient with insulin-dependent diabetes mellitus

J Int Med Res. 1991 Jul-Aug;19(4):348-50. doi: 10.1177/030006059101900408.

Abstract

A 41-year old male with insulin-dependent diabetes mellitus previously unsuccessfully treated with a controlled diet and glibenclamide, and subsequently with increasing insulin doses (5 and 20 IU/day) experienced polyuria, glycosuria and loss of weight. On admittance to hospital serum C3 concentrations were found to be depressed. The insulin dose was further increased to 30 IU/day and the patient was also treated with 20 mg nafamostat mesylate given intravenously twice daily for 6 days. On completion of nafamostat mesylate treatment serum C3 concentrations were increased but after 17 days they started to decrease again.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Benzamidines
  • Blood Glucose / analysis
  • Complement Activation* / drug effects
  • Complement C3 / analysis
  • Complement C3 / deficiency
  • Complement Pathway, Alternative*
  • Diabetes Mellitus, Type 1 / immunology*
  • Guanidines / pharmacology
  • Guanidines / therapeutic use
  • Humans
  • Male

Substances

  • Benzamidines
  • Blood Glucose
  • Complement C3
  • Guanidines
  • nafamostat